Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?
|
摘要
Sorafenib has been considered the standard of care for patients with advanced unresectable hepatocellular carcinoma(HCC) since 2007 and numerous studieshave investigated the role of markers involved in the angiogenesis process at both the expression and genetic level and clinical aspect. What results have ten years of research produced? Several clinical and biological markers are associated with prognosis. The most interesting clinical parameters are adverse events, Barcelona Clinic Liver Cancer stage, and macroscopic vascular invasion, while several single nucleotide polymorphisms and plasma angiopoietin-2 levels represent the most promising biological biomarkers. A recent pooled analysis of two phase III randomized trials showed that the neutrophil-to-lymphocyte ratio, etiology and extra-hepatic spread are predictive factors of response to sorafenib, but did not identify any predictive biological markers. After 10 years of research into sorafenib there are still no validated prognostic or predictive factors of response to the drug in HCC. The aim of the present review was to summarize 10 years of research into sorafenib, looking in particular at the potential of associated clinical and biological markers to predict its efficacy in patients with advanced HCC.
Sorafenib has been considered the standard of care for patients with advanced unresectable hepatocellular carcinoma(HCC) since 2007 and numerous studieshave investigated the role of markers involved in the angiogenesis process at both the expression and genetic level and clinical aspect. What results have ten years of research produced? Several clinical and biological markers are associated with prognosis. The most interesting clinical parameters are adverse events, Barcelona Clinic Liver Cancer stage, and macroscopic vascular invasion, while several single nucleotide polymorphisms and plasma angiopoietin-2 levels represent the most promising biological biomarkers. A recent pooled analysis of two phase III randomized trials showed that the neutrophil-to-lymphocyte ratio, etiology and extra-hepatic spread are predictive factors of response to sorafenib, but did not identify any predictive biological markers. After 10 years of research into sorafenib there are still no validated prognostic or predictive factors of response to the drug in HCC. The aim of the present review was to summarize 10 years of research into sorafenib, looking in particular at the potential of associated clinical and biological markers to predict its efficacy in patients with advanced HCC.
Sorafenib has been considered the standard of care for patients with advanced unresectable hepatocellular carcinoma(HCC) since 2007 and numerous studieshave investigated the role of markers involved in the angiogenesis process at both the expression and genetic level and clinical aspect. What results have ten years of research produced? Several clinical and biological markers are associated with prognosis. The most interesting clinical parameters are adverse events, Barcelona Clinic Liver Cancer stage, and macroscopic vascular invasion, while several single nucleotide polymorphisms and plasma angiopoietin-2 levels represent the most promising biological biomarkers. A recent pooled analysis of two phase III randomized trials showed that the neutrophil-to-lymphocyte ratio, etiology and extra-hepatic spread are predictive factors of response to sorafenib, but did not identify any predictive biological markers. After 10 years of research into sorafenib there are still no validated prognostic or predictive factors of response to the drug in HCC. The aim of the present review was to summarize 10 years of research into sorafenib, looking in particular at the potential of associated clinical and biological markers to predict its efficacy in patients with advanced HCC.
引文
1 Llovet JM,Ricci S,Mazzaferro V,Hilgard P,Gane E,Blanc JF,de Oliveira AC,Santoro A,Raoul JL,Forner A,Schwartz M,Porta C,Zeuzem S,Bolondi L,Greten TF,Galle PR,Seitz JF,Borbath I,H?ussinger D,Giannaris T,Shan M,Moscovici M,Voliotis D,Bruix J;SHARP Investigators Study Group.Sorafenib in advanced hepatocellular carcinoma.N Engl J Med 2008;359:378-390[PMID:18650514 DOI:10.1056/NEJMoa0708857]
2 Cervello M,Bachvarov D,Lampiasi N,Cusimano A,Azzolina A,McCubrey JA,Montalto G.Molecular mechanisms of sorafenib action in liver cancer cells.Cell Cycle 2012;11:2843-2855[PMID:22801548 DOI:10.4161/cc.21193]
3 Tai WT,Cheng AL,Shiau CW,Huang HP,Huang JW,Chen PJ,Chen KF.Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma.J Hepatol 2011;55:1041-1048[PMID:21354226DOI:10.1016/j.jhep.2011.01.047]
4 Llovet JM,Pe?a CE,Lathia CD,Shan M,Meinhardt G,Bruix J;SHARP Investigators Study Group.Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma.Clin Cancer Res 2012;18:2290-2300[PMID:22374331 DOI:10.1158/1078-0432.CCR-11-2175]
5 Forner A,Llovet JM,Bruix J.Hepatocellular carcinoma.Lancet 2012;379:1245-1255[PMID:22353262 DOI:10.1016/S0140-6736(11)61347-0]
6 Bruix J,Cheng AL,Meinhardt G,Nakajima K,De Sanctis Y,Llovet J.Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma:Analysis of two phase IIIstudies.J Hepatol 2017;67:999-1008[PMID:28687477 DOI:10.1016/j.jhep.2017.06.026]
7 Lin ZZ,Hsu C,Hu FC,Shao YY,Chang DY,Yang CH,Hong RL,Hsu CH,Cheng AL.Factors impacting prognosis prediction in BCLC stage C and Child-Pugh class A hepatocellular carcinoma patients in prospective clinical trials of systemic therapy.Oncologist 2012;17:970-977[PMID:22673633 DOI:10.1634/theoncologist.2011-0411]
8 Shao YY,Lin ZZ,Hsu C,Shen YC,Hsu CH,Cheng AL.Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma.Cancer 2010;116:4590-4596[PMID:20572033 DOI:10.1002/cncr.25257]
9 Yau T,Yao TJ,Chan P,Wong H,Pang R,Fan ST,Poon RT.The significance of early alpha-fetoprotein level changes in predicting clinical and survival benefits in advanced hepatocellular carcinoma patients receiving sorafenib.Oncologist 2011;16:1270-1279[PMID:21885876 DOI:10.1634/theoncologist.2011-0105]
10 Personeni N,Bozzarelli S,Pressiani T,Rimassa L,Tronconi MC,Sclafani F,Carnaghi C,Pedicini V,Giordano L,Santoro A.Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma.J Hepatol 2012;57:101-107[PMID:22414760 DOI:10.1016/j.jhep.2012.02.016]
11 Nakazawa T,Hidaka H,Takada J,Okuwaki Y,Tanaka Y,Watanabe M,Shibuya A,Minamino T,Kokubu S,Koizumi W.Early increase inα-fetoprotein for predicting unfavorable clinical outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib.Eur J Gastroenterol Hepatol 2013;25:683-689[PMID:23395995 DOI:10.1097/MEG.0b013e32835d913b]
12 Vincenzi B,Santini D,Russo A,Addeo R,Giuliani F,Montella L,Rizzo S,Venditti O,Frezza AM,Caraglia M,Colucci G,Del Prete S,Tonini G.Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib.Oncologist 2010;15:85-92[PMID:20051477 DOI:10.1634/theoncologist.2009-0143]
13 Reig M,Torres F,Rodriguez-Lope C,Forner A,LLarch N,Rimola J,Darnell A,Ríos J,Ayuso C,Bruix J.Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib.J Hepatol 2014;61:318-324[PMID:24703956 DOI:10.1016/j.jhep.2014.03.030]
14 Wang P,Tan G,Zhu M,Li W,Zhai B,Sun X.Hand-foot skin reaction is a beneficial indicator of sorafenib therapy for patients with hepatocellular carcinoma:a systemic review and metaanalysis.Expert Rev Gastroenterol Hepatol 2018;12:1-8[PMID:28847184 DOI:10.1080/17474124.2017.1373018]
15 Scartozzi M,Galizia E,Chiorrini S,Giampieri R,Berardi R,Pierantoni C,Cascinu S.Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab.Ann Oncol 2009;20:227-230[PMID:18842611DOI:10.1093/annonc/mdn637]
16 Casadei Gardini A,Scarpi E,Marisi G,Foschi FG,Donati G,Giampalma E,Faloppi L,Scartozzi M,Silvestris N,Bisulli M,Corbelli J,Gardini A,La Barba G,Veneroni L,Tamberi S,Cascinu S,Frassineti GL.Early onset of hypertension and serum electrolyte changes as potential predictive factors of activity in advanced HCCpatients treated with sorafenib:results from a retrospective analysis of the HCC-AVR group.Oncotarget 2016;7:15243-15251[PMID:26893366 DOI:10.18632/oncotarget.7444]
17 Zhong BY,Ni CF,Chen L,Zhu HD,Teng GJ.Early Sorafenibrelated Biomarkers for Combination Treatment with Transarterial Chemoembolization and Sorafenib in Patients with Hepatocellular Carcinoma.Radiology 2017;284:583-592[PMID:28263701DOI:10.1148/radiol.2017161975]
18 Howell J,Pinato DJ,Ramaswami R,Bettinger D,Arizumi T,Ferrari C,Yen C,Gibbin A,Burlone ME,Guaschino G,Sellers L,Black J,Pirisi M,Kudo M,Thimme R,Park JW,Sharma R.On-target sorafenib toxicity predicts improved survival in hepatocellular carcinoma:a multi-centre,prospective study.Aliment Pharmacol Ther 2017;45:1146-1155[PMID:28252185DOI:10.1111/apt.13977]
19 Shin SY,Lee YJ.Correlation of skin toxicity and hypertension with clinical benefit in advanced hepatocellular carcinoma patients treated with sorafenib.Int J Clin Pharmacol Ther 2013;51:837-846[PMID:24075093 DOI:10.5414/CP201907]
20 Otsuka T,Eguchi Y,Kawazoe S,Yanagita K,Ario K,Kitahara K,Kawasoe H,Kato H,Mizuta T;Saga Liver Cancer Study Group.Skin toxicities and survival in advanced hepatocellular carcinoma patients treated with sorafenib.Hepatol Res 2012;42:879-886[PMID:22469363 DOI:10.1111/j.1872-034X.2012.00991.x]
21 Bettinger D,Schultheiss M,Knüppel E,Thimme R,Blum HE,Spangenberg HC.Diarrhea predicts a positive response to sorafenib in patients with advanced hepatocellular carcinoma.Hepatology2012;56:789-790[PMID:22307848 DOI:10.1002/hep.25637]
22 Koschny R,Gotthardt D,Koehler C,Jaeger D,Stremmel W,Ganten TM.Diarrhea is a positive outcome predictor for sorafenib treatment of advanced hepatocellular carcinoma.Oncology2013;84:6-13[PMID:23075905 DOI:10.1159/000342425]
23 Di Costanzo GG,de Stefano G,Tortora R,Farella N,Addario L,Lampasi F,Lanza AG,Cordone G,Imparato M,Caporaso N.Sorafenib off-target effects predict outcomes in patients treated for hepatocellular carcinoma.Future Oncol 2015;11:943-951[PMID:25760975 DOI:10.2217/fon.14.291]
24 Di Costanzo GG,Casadei Gardini A,Marisi G,Foschi FG,Scartozzi M,Granata R,Faloppi L,Cascinu S,Silvestris N,Brunetti O,Palmieri VO,Ercolani G,Tortora R.Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma.Target Oncol 2017;12:795-803[PMID:28770532 DOI:10.1007/s11523-017-0522-5]
25 Abdel-Rahman O,Lamarca A.Development of sorafenib-related side effects in patients diagnosed with advanced hepatocellular carcinoma treated with sorafenib:a systematic-review and metaanalysis of the impact on survival.Expert Rev Gastroenterol Hepatol 2017;11:75-83[PMID:27882800 DOI:10.1080/17474124.2017.1264874]
26 Cheng AL,Guan Z,Chen Z,Tsao CJ,Qin S,Kim JS,Yang TS,Tak WY,Pan H,Yu S,Xu J,Fang F,Zou J,Lentini G,Voliotis D,Kang YK.Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status:subset analyses of the phase III Sorafenib Asia-Pacific trial.Eur J Cancer 2012;48:1452-1465[PMID:22240282 DOI:10.1016/j.ejca.2011.12.006]
27 Hollebecque A,Cattan S,Romano O,Sergent G,Mourad A,Louvet A,Dharancy S,Boleslawski E,Truant S,Pruvot FR,Hebbar M,Ernst O,Mathurin P.Safety and efficacy of sorafenib in hepatocellular carcinoma:the impact of the Child-Pugh score.Aliment Pharmacol Ther 2011;34:1193-1201[PMID:21958438DOI:10.1111/j.1365-2036.2011.04860.x]
28 Pressiani T,Boni C,Rimassa L,Labianca R,Fagiuoli S,Salvagni S,Ferrari D,Cortesi E,Porta C,Mucciarini C,Latini L,Carnaghi C,Banzi M,Fanello S,De Giorgio M,Lutman FR,Torzilli G,Tommasini MA,Ceriani R,Covini G,Tronconi MC,Giordano L,Locopo N,Naimo S,Santoro A.Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma:a prospective feasibility analysis.Ann Oncol 2013;24:406-411[PMID:23041587 DOI:10.1093/annonc/mds343]
29 Marrero JA,Kudo M,Venook AP,Ye SL,Bronowicki JP,Chen XP,Dagher L,Furuse J,Geschwind JH,de Guevara LL,Papandreou C,Takayama T,Sanyal AJ,Yoon SK,Nakajima K,Lehr R,Heldner S,Lencioni R.Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups:The GIDEONstudy.J Hepatol 2016;65:1140-1147[PMID:27469901 DOI:10.1016/j.jhep.2016.07.020]
30 Lee S,Kang JH,Kim DY,Ahn SH,Park JY,Kim BK,Kim SU,Han KH.Prognostic factors of sorafenib therapy in hepatocellular carcinoma patients with failure of transarterial chemoembolization.Hepatol Int 2017;11:292-299[PMID:28324324 DOI:10.1007/s12072-017-9792-3]
31 Peng S,Zhao Y,Xu F,Jia C,Xu Y,Dai C.An updated metaanalysis of randomized controlled trials assessing the effect of sorafenib in advanced hepatocellular carcinoma.PLo S One2014;9:e112530[PMID:25460347 DOI:10.1371/journal.pone.0112530]
32 Iavarone M,Cabibbo G,Piscaglia F,Zavaglia C,Grieco A,Villa E,CammàC,Colombo M;SOFIA(SOraFenib Italian Assessment)study group.Field-practice study of sorafenib therapy for hepatocellular carcinoma:a prospective multicenter study in Italy.Hepatology 2011;54:2055-2063[PMID:21898496 DOI:10.1002/hep.24644]
33 Casadei Gardini A,Frassineti GL,Foschi FG,Ercolani G,Ulivi P.Sorafenib and Regorafenib in HBV-or HCV-positive hepatocellular carcinoma patients:Analysis of RESORCE and SHARP trials.Dig Liver Dis 2017;49:943-944[PMID:28546063DOI:10.1016/j.dld.2017.04.022]
34 Donadon V,Balbi M,Mas MD,Casarin P,Zanette G.Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease.Liver Int 2010;30:750-758[PMID:20331505 DOI:10.1111/j.1478-3231.2010.02223.x]
35 Casadei Gardini A,Marisi G,Scarpi E,Scartozzi M,Faloppi L,Silvestris N,Masi G,Vivaldi C,Brunetti O,Tamberi S,Foschi FG,Tamburini E,Tenti E,Ricca Rosellini S,Ulivi P,Cascinu S,Nanni O,Frassineti GL.Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib.Expert Opin Pharmacother 2015;16:2719-2725[PMID:26513009 DOI:10.1517/14656566.2015.1102887]
36 Casadei Gardini A,Faloppi L,De Matteis S,Foschi FG,Silvestris N,Tovoli F,Palmieri V,Marisi G,Brunetti O,VespasianiGentilucci U,Perrone G,Valgiusti M,Granato AM,Ercolani G,Negrini G,Tamburini E,Aprile G,Passardi A,Santini D,Cascinu S,Frassineti GL,Scartozzi M.Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib:Validation study and biological rationale.Eur J Cancer 2017;86:106-114[PMID:28985579 DOI:10.1016/j.ejca.2017.09.003]
37 De Matteis S,Granato AM,Napolitano R,Molinari C,Valgiusti M,Santini D,Foschi FG,Ercolani G,Vespasiani Gentilucci U,Faloppi L,Scartozzi M,Frassineti GL,Casadei Gardini A.Interplay Between SIRT-3,Metabolism and Its Tumor Suppressor Role in Hepatocellular Carcinoma.Dig Dis Sci 2017;62:1872-1880[PMID:28527050 DOI:10.1007/s10620-017-4615-x]
38 Di Costanzo GG,Tortora R,Morisco F,Addario L,Guarino M,Cordone G,Falco L,Caporaso N.Impact of Diabetes on Outcomes of Sorafenib Therapy for Hepatocellular Carcinoma.Target Oncol 2017;12:61-67[PMID:27503006 DOI:10.1007/s11523-016-0454-5]
39 Ferrucci PF,Gandini S,Battaglia A,Alfieri S,Di Giacomo AM,Giannarelli D,Cappellini GC,De Galitiis F,Marchetti P,Amato G,Lazzeri A,Pala L,Cocorocchio E,Martinoli C.Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients.Br J Cancer 2015;112:1904-1910[PMID:26010413 DOI:10.1038/bjc.2015.180]
40 Hu B,Yang XR,Xu Y,Sun YF,Sun C,Guo W,Zhang X,Wang WM,Qiu SJ,Zhou J,Fan J.Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma.Clin Cancer Res 2014;20:6212-6222[PMID:25271081 DOI:10.1158/1078-0432.CCR-14-0442]
41 Casadei Gardini A,Scarpi E,Faloppi L,Scartozzi M,Silvestris N,Santini D,de Stefano G,Marisi G,Negri FV,Foschi FG,Valgiusti M,Ercolani G,Frassineti GL.Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib.Oncotarget 2016;7:67142-67149[PMID:27613839 DOI:10.18632/oncotarget.11565]
42 Howell J,Pinato DJ,Ramaswami R,Arizumi T,Ferrari C,Gibbin A,Burlone ME,Guaschino G,Toniutto P,Black J,Sellers L,Kudo M,Pirisi M,Sharma R.Integration of the cancer-related inflammatory response as a stratifying biomarker of survival in hepatocellular carcinoma treated with sorafenib.Oncotarget 2017;8:36161-36170[PMID:28212535 DOI:10.18632/oncotarget.15322]
43 da Fonseca LG,Barroso-Sousa R,Bento Ada S,Blanco BP,Valente GL,Pfiffer TE,Hoff PM,Sabbaga J.Pre-treatment neutrophil-to-lymphocyte ratio affects survival in patients with advanced hepatocellular carcinoma treated with sorafenib.Med Oncol 2014;31:264[PMID:25273866 DOI:10.1007/s12032-014-0264-5]
44 LuéA,Serrano MT,Bustamante FJ,I?arrairaegui M,Arenas JI,Testillano M,Lorente S,Gil C,de la Torre M,Gomez A,Sangro B.Neutrophil-to-lymphocyte ratio predicts survival in European patients with hepatocellular carcinoma administered sorafenib.Oncotarget 2017;8:103077-103086[PMID:29262546 DOI:10.18632/oncotarget.21528]
45 Therasse P,Arbuck SG,Eisenhauer EA,Wanders J,Kaplan RS,Rubinstein L,Verweij J,Van Glabbeke M,van Oosterom AT,Christian MC,Gwyther SG.New guidelines to evaluate the response to treatment in solid tumors.European Organization for Research and Treatment of Cancer,National Cancer Institute of the United States,National Cancer Institute of Canada.J Natl Cancer Inst 2000;92:205-216[PMID:10655437]
46 Eisenhauer EA,Therasse P,Bogaerts J,Schwartz LH,Sargent D,Ford R,Dancey J,Arbuck S,Gwyther S,Mooney M,Rubinstein L,Shankar L,Dodd L,Kaplan R,Lacombe D,Verweij J.New response evaluation criteria in solid tumours:revised RECISTguideline(version 1.1).Eur J Cancer 2009;45:228-247[PMID:19097774 DOI:10.1016/j.ejca.2008.10.026]
47 Ronot M,Bouattour M,Wassermann J,Bruno O,Dreyer C,Larroque B,Castera L,Vilgrain V,Belghiti J,Raymond E,Faivre S.Alternative Response Criteria(Choi,European association for the study of the liver,and modified Response Evaluation Criteria in Solid Tumors[RECIST])Versus RECIST 1.1 in patients with advanced hepatocellular carcinoma treated with sorafenib.Oncologist 2014;19:394-402[PMID:24652387 DOI:10.1634/theoncologist.2013-0114]
48 Sugimoto K,Moriyasu F,Saito K,Rognin N,Kamiyama N,Furuichi Y,Imai Y.Hepatocellular carcinoma treated with sorafenib:early detection of treatment response and major adverse events by contrast-enhanced US.Liver Int 2013;33:605-615[PMID:23305331 DOI:10.1111/liv.12098]
49 Zocco MA,Garcovich M,Lupascu A,Di Stasio E,Roccarina D,Annicchiarico BE,Riccardi L,Ainora ME,Ponziani F,Caracciolo G,Rapaccini GL,Landolfi R,Siciliano M,Pompili M,Gasbarrini A.Early prediction of response to sorafenib in patients with advanced hepatocellular carcinoma:the role of dynamic contrast enhanced ultrasound.J Hepatol 2013;59:1014-1021[PMID:23811306 DOI:10.1016/j.jhep.2013.06.011]
50 Zhou C,Liu J,Li Y,Liu L,Zhang X,Ma CY,Hua SC,Yang M,Yuan Q.microRNA-1274a,a modulator of sorafenib induced a disintegrin and metalloproteinase 9(ADAM9)down-regulation in hepatocellular carcinoma.FEBS Lett 2011;585:1828-1834[PMID:21530512 DOI:10.1016/j.febslet.2011.04.040]
51 Hsu CY,Shen YC,Yu CW,Hsu C,Hu FC,Hsu CH,Chen BB,Wei SY,Cheng AL,Shih TT.Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil.J Hepatol 2011;55:858-865[PMID:21338641 DOI:10.1016/j.jhep.2011.01.032]
52 Lee JH,Park JY,Kim DY,Ahn SH,Han KH,Seo HJ,Lee JD,Choi HJ.Prognostic value of 18F-FDG PET for hepatocellular carcinoma patients treated with sorafenib.Liver Int 2011;31:1144-1149[PMID:21745288 DOI:10.1111/j.1478-3231.2011.02541.x]
53 MuléS,Thiefin G,Costentin C,Durot C,Rahmouni A,Luciani A,Hoeffel C.Advanced Hepatocellular Carcinoma:Pretreatment Contrast-enhanced CT Texture Parameters as Predictive Biomarkers of Survival in Patients Treated with Sorafenib.Radiology 2018;288:445-455[PMID:29584597 DOI:10.1148/radiol.2018171320]
54 Su WW,Lee KT,Yeh YT,Soon MS,Wang CL,Yu ML,Wang SN.Association of circulating insulin-like growth factor 1 with hepatocellular carcinoma:one cross-sectional correlation study.JClin Lab Anal 2010;24:195-200[PMID:20486202 DOI:10.1002/jcla.20320]
55 Shao YY,Huang CC,Lin SD,Hsu CH,Cheng AL.Serum insulinlike growth factor-1 levels predict outcomes of patients with advanced hepatocellular carcinoma receiving antiangiogenic therapy.Clin Cancer Res 2012;18:3992-3997[PMID:22623732DOI:10.1158/1078-0432.CCR-11-2853]
56 Kim HY,Lee DH,Lee JH,Cho YY,Cho EJ,Yu SJ,Kim YJ,Yoon JH.Novel biomarker-based model for the prediction of sorafenib response and overall survival in advanced hepatocellular carcinoma:a prospective cohort study.BMC Cancer 2018;18:307[PMID:29558905 DOI:10.1186/s12885-018-4211-2]
57 Miyahara K,Nouso K,Tomoda T,Kobayashi S,Hagihara H,Kuwaki K,Toshimori J,Onishi H,Ikeda F,Miyake Y,Nakamura S,Shiraha H,Takaki A,Yamamoto K.Predicting the treatment effect of sorafenib using serum angiogenesis markers in patients with hepatocellular carcinoma.J Gastroenterol Hepatol 2011;26:1604-1611[PMID:22011296 DOI:10.1111/j.1440-1746.2011.06887.x]
58 Tsuchiya K,Asahina Y,Matsuda S,Muraoka M,Nakata T,Suzuki Y,Tamaki N,Yasui Y,Suzuki S,Hosokawa T,Nishimura T,Ueda K,Kuzuya T,Nakanishi H,Itakura J,Takahashi Y,Kurosaki M,Enomoto N,Izumi N.Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma.Cancer 2014;120:229-237[PMID:24122122 DOI:10.1002/cncr.28384]
59 Hu B,Cheng SY.Angiopoietin-2:development of inhibitors for cancer therapy.Curr Oncol Rep 2009;11:111-116[PMID:19216842]
60 Hayashi T,Yamashita T,Terashima T,Suda T,Okada H,Asahina Y,Hayashi T,Hara Y,Nio K,Sunagozaka H,Takatori H,Arai K,Sakai Y,Yamashita T,Mizukoshi E,Honda M,Kaneko S.Serum cytokine profiles predict survival benefits in patients with advanced hepatocellular carcinoma treated with sorafenib:a retrospective cohort study.BMC Cancer 2017;17:870[PMID:29258450 DOI:10.1186/s12885-017-3889-x]
61 Villanueva A,Minguez B,Forner A,Reig M,Llovet JM.Hepatocellular carcinoma:novel molecular approaches for diagnosis,prognosis,and therapy.Annu Rev Med 2010;61:317-328[PMID:20059340 DOI:10.1146/annurev.med.080608.100623]
62 Sakai K,Takeda H,Nishijima N,Orito E,Joko K,Uchida Y,Izumi N,Nishio K,Osaki Y.Targeted DNA and RNA sequencing of fine-needle biopsy FFPE specimens in patients with unresectable hepatocellular carcinoma treated with sorafenib.Oncotarget2015;6:21636-21644[PMID:26046304 DOI:10.18632/oncotarget.4270]
63 Kan Z,Zheng H,Liu X,Li S,Barber TD,Gong Z,Gao H,Hao K,Willard MD,Xu J,Hauptschein R,Rejto PA,Fernandez J,Wang G,Zhang Q,Wang B,Chen R,Wang J,Lee NP,Zhou W,Lin Z,Peng Z,Yi K,Chen S,Li L,Fan X,Yang J,Ye R,Ju J,Wang K,Estrella H,Deng S,Wei P,Qiu M,Wulur IH,Liu J,Ehsani ME,Zhang C,Loboda A,Sung WK,Aggarwal A,Poon RT,Fan ST,Wang J,Hardwick J,Reinhard C,Dai H,Li Y,Luk JM,Mao M.Wholegenome sequencing identifies recurrent mutations in hepatocellular carcinoma.Genome Res 2013;23:1422-1433[PMID:23788652DOI:10.1101/gr.154492.113]
64 Cleary SP,Jeck WR,Zhao X,Chen K,Selitsky SR,Savich GL,Tan TX,Wu MC,Getz G,Lawrence MS,Parker JS,Li J,Powers S,Kim H,Fischer S,Guindi M,Ghanekar A,Chiang DY.Identification of driver genes in hepatocellular carcinoma by exome sequencing.Hepatology 2013;58:1693-1702[PMID:23728943DOI:10.1002/hep.26540]
65 Scartozzi M,Faloppi L,Svegliati Baroni G,Loretelli C,Piscaglia F,Iavarone M,Toniutto P,Fava G,De Minicis S,Mandolesi A,Bianconi M,Giampieri R,Granito A,Facchetti F,Bitetto D,Marinelli S,Venerandi L,Vavassori S,Gemini S,D’Errico A,Colombo M,Bolondi L,Bearzi I,Benedetti A,Cascinu S.VEGFand VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib:the ALICE-1 study.Int J Cancer2014;135:1247-1256[PMID:24510746 DOI:10.1002/ijc.28772]
66 Casadei Gardini A,Marisi G,Faloppi L,Scarpi E,Foschi FG,Iavarone M,Lauletta G,Corbelli J,Valgiusti M,Facchetti F,Della Corte C,Neri LM,Tamberi S,Cascinu S,Scartozzi M,Amadori D,Nanni O,Tenti E,Ulivi P,Frassineti GL.eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib:final results of the ePHAS study.Oncotarget 2016;7:27988-27999[PMID:27058899 DOI:10.18632/oncotarget.8569]
67 Marisi G,Scartozzi M,Faloppi L,Foschi GF,Lauletta G,Valgiusti M,Aprile G,Fornaro L,Iavarone M,Ercolani G,Frassineti GL,Amadori D,Casadei Gardini A.Ang-2 polymorphisms in relation to outcome in advanced HCC patients receiving sorafenib.J Clin Oncol 2017;35 Suppl 15:e15666[DOI:10.1200/JCO.2017.35.15_suppl.e15666]
68 Faloppi L,Casadei Gardini A,Masi G,Silvestris N,Loretelli C,Ulivi P,Vivaldi C,Bianconi M,Giampieri R,Bittoni A,Andrikou K,Del Prete M,Scartozzi M,Cascinu S.Angiogenesis polymorphisms profile in the prediction of clinical outcome of advanced HCCpatients receiving sorafenib:Combined analysis of VEGF and HIF-1α.Final results of the ALICE-2 study.J Clin Oncol 2016;34Suppl 4:280[DOI:10.1200/jco.2016.34.4_suppl.280]
69 Casadei Gardini A,Faloppi L,Aprile G,Brunetti O,Caparello C,Corbelli J,Chessa L,Bruno D,Ercolani G,Leonetti A,de Stefano G,Farella N,Foschi FG,Lanzi A,Dadduzio V,Marisi G,Masi G,Negri FV,Pagan F,Santini D,Scarpi E,Silletta M,Silvestris N,Tamburini E,Tassinari D,Vivaldi C,Gentilucci UV,Zagonel V,Calvetti L,Cascinu S,Frassineti GL,Scartozzi M.Multicenter Prospective Study of Angiogenesis Polymorphism Validation in HCC Patients Treated with Sorafenib.An INNOVATE Study Protocol.Tumori 2017;:tj5000704 Epub ahead of print[PMID:29739298 DOI:10.5301/tj.5000704]
70 Horwitz E,Stein I,Andreozzi M,Nemeth J,Shoham A,Pappo O,Schweitzer N,Tornillo L,Kanarek N,Quagliata L,Zreik F,Porat RM,Finkelstein R,Reuter H,Koschny R,Ganten T,Mogler C,Shibolet O,Hess J,Breuhahn K,Grunewald M,Schirmacher P,Vogel A,Terracciano L,Angel P,Ben-Neriah Y,Pikarsky E.Human and mouse VEGFA-amplified hepatocellular carcinomas are highly sensitive to sorafenib treatment.Cancer Discov 2014;4:730-743[PMID:24687604 DOI:10.1158/2159-8290.CD-13-0782]
71 Arao T,Ueshima K,Matsumoto K,Nagai T,Kimura H,Hagiwara S,Sakurai T,Haji S,Kanazawa A,Hidaka H,Iso Y,Kubota K,Shimada M,Utsunomiya T,Hirooka M,Hiasa Y,Toyoki Y,Hakamada K,Yasui K,Kumada T,Toyoda H,Sato S,Hisai H,Kuzuya T,Tsuchiya K,Izumi N,Arii S,Nishio K,Kudo M.FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma.Hepatology 2013;57:1407-1415[PMID:22890726 DOI:10.1002/hep.25956]
72 He C,Dong X,Zhai B,Jiang X,Dong D,Li B,Jiang H,Xu S,Sun X.MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.Oncotarget 2015;6:28867-28881[PMID:26311740DOI:10.18632/oncotarget.4814]
73 Xu Y,Huang J,Ma L,Shan J,Shen J,Yang Z,Liu L,Luo Y,Yao C,Qian C.MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways.Cancer Lett 2016;371:171-181[PMID:26655273 DOI:10.1016/j.canlet.2015.11.034]
74 Vaira V,Roncalli M,Carnaghi C,Faversani A,Maggioni M,Augello C,Rimassa L,Pressiani T,Spagnuolo G,Di Tommaso L,Fagiuoli S,Rota Caremoli E,Barberis M,Labianca R,Santoro A,Bosari S.MicroRNA-425-3p predicts response to sorafenib therapy in patients with hepatocellular carcinoma.Liver Int 2015;35:1077-1086[PMID:25040368 DOI:10.1111/liv.12636]
75 Gy?ngy?si B,Véghé,Járay B,Székely E,Fassan M,Bodoky G,Schaff Z,Kiss A.Pretreatment MicroRNA Level and Outcome in Sorafenib-treated Hepatocellular Carcinoma.J Histochem Cytochem 2014;62:547-555[PMID:24804874 DOI:10.1369/0022155414537277]
76 Fornari F,Pollutri D,Patrizi C,La Bella T,Marinelli S,Casadei Gardini A,Marisi G,Baron Toaldo M,Baglioni M,Salvatore V,Callegari E,Baldassarre M,Galassi M,Giovannini C,Cescon M,Ravaioli M,Negrini M,Bolondi L,Gramantieri L.In Hepatocellular Carcinoma miR-221 Modulates Sorafenib Resistance through Inhibition of Caspase-3-Mediated Apoptosis.Clin Cancer Res2017;23:3953-3965[PMID:28096271 DOI:10.1158/1078-0432.CCR-16-1464]
77 Nishida N,Arizumi T,Hagiwara S,Ida H,Sakurai T,Kudo M.MicroRNAs for the Prediction of Early Response to Sorafenib Treatment in Human Hepatocellular Carcinoma.Liver Cancer2017;6:113-125[PMID:28275578 DOI:10.1159/000449475]
78 Stiuso P,Potenza N,Lombardi A,Ferrandino I,Monaco A,Zappavigna S,Vanacore D,Mosca N,Castiello F,Porto S,Addeo R,Prete SD,De Vita F,Russo A,Caraglia M.MicroRNA-423-5p Promotes Autophagy in Cancer Cells and Is Increased in Serum From Hepatocarcinoma Patients Treated With Sorafenib.Mol Ther Nucleic Acids 2015;4:e233[PMID:25782064 DOI:10.1038/mtna.2015.8]
79 Yoon EL,Yeon JE,Ko E,Lee HJ,Je JH,Yoo YJ,Kang SH,Suh SJ,Kim JH,Seo YS,Yim HJ,Byun KS.An Explorative Analysis for the Role of Serum miR-10b-3p Levels in Predicting Response to Sorafenib in Patients with Advanced Hepatocellular Carcinoma.J Korean Med Sci 2017;32:212-220[PMID:28049231 DOI:10.3346/jkms.2017.32.2.212]
80 Carvajal-Hausdorf DE,Schalper KA,Neumeister VM,Rimm DL.Quantitative measurement of cancer tissue biomarkers in the lab and in the clinic.Lab Invest 2015;95:385-396[PMID:25502176 DOI:10.1038/labinvest.2014.157]
81 Abou-Alfa GK,Schwartz L,Ricci S,Amadori D,Santoro A,Figer A,De Greve J,Douillard JY,Lathia C,Schwartz B,Taylor I,Moscovici M,Saltz LB.Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.J Clin Oncol 2006;24:4293-4300[PMID:16908937 DOI:10.1200/JCO.2005.01.3441]
82 Personeni N,Rimassa L,Pressiani T,Destro A,Ligorio C,Tronconi MC,Bozzarelli S,Carnaghi C,Di Tommaso L,Giordano L,Roncalli M,Santoro A.Molecular determinants of outcome in sorafenib-treated patients with hepatocellular carcinoma.J Cancer Res Clin Oncol 2013;139:1179-1187[PMID:23568548 DOI:10.1007/s00432-013-1429-x]
83 Chen D,Zhao P,Li SQ,Xiao WK,Yin XY,Peng BG,Liang LJ.Prognostic impact of pERK in advanced hepatocellular carcinoma patients treated with sorafenib.Eur J Surg Oncol 2013;39:974-980[PMID:23845703 DOI:10.1016/j.ejso.2013.06.018]
84 Chu JS,Ge FJ,Zhang B,Wang Y,Silvestris N,Liu LJ,Zhao CH,Lin L,Brunetti AE,Fu YL,Wang J,Paradiso A,Xu JM.Expression and prognostic value of VEGFR-2,PDGFR-β,and c-Met in advanced hepatocellular carcinoma.J Exp Clin Cancer Res 2013;32:16[PMID:23552472 DOI:10.1186/1756-9966-32-16]
85 Hagiwara S,Kudo M,Nagai T,Inoue T,Ueshima K,Nishida N,Watanabe T,Sakurai T.Activation of JNK and high expression level of CD133 predict a poor response to sorafenib in hepatocellular carcinoma.Br J Cancer 2012;106:1997-2003[PMID:22596232 DOI:10.1038/bjc.2012.145]
86 Kudo M,Finn RS,Qin S,Han KH,Ikeda K,Piscaglia F,Baron A,Park JW,Han G,Jassem J,Blanc JF,Vogel A,Komov D,Evans TRJ,Lopez C,Dutcus C,Guo M,Saito K,Kraljevic S,Tamai T,Ren M,Cheng AL.Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma:a randomised phase 3 non-inferiority trial.Lancet2018;391:1163-1173[PMID:29433850 DOI:10.1016/S0140-6736(18)30207-1]
2 Cervello M,Bachvarov D,Lampiasi N,Cusimano A,Azzolina A,McCubrey JA,Montalto G.Molecular mechanisms of sorafenib action in liver cancer cells.Cell Cycle 2012;11:2843-2855[PMID:22801548 DOI:10.4161/cc.21193]
3 Tai WT,Cheng AL,Shiau CW,Huang HP,Huang JW,Chen PJ,Chen KF.Signal transducer and activator of transcription 3 is a major kinase-independent target of sorafenib in hepatocellular carcinoma.J Hepatol 2011;55:1041-1048[PMID:21354226DOI:10.1016/j.jhep.2011.01.047]
4 Llovet JM,Pe?a CE,Lathia CD,Shan M,Meinhardt G,Bruix J;SHARP Investigators Study Group.Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma.Clin Cancer Res 2012;18:2290-2300[PMID:22374331 DOI:10.1158/1078-0432.CCR-11-2175]
5 Forner A,Llovet JM,Bruix J.Hepatocellular carcinoma.Lancet 2012;379:1245-1255[PMID:22353262 DOI:10.1016/S0140-6736(11)61347-0]
6 Bruix J,Cheng AL,Meinhardt G,Nakajima K,De Sanctis Y,Llovet J.Prognostic factors and predictors of sorafenib benefit in patients with hepatocellular carcinoma:Analysis of two phase IIIstudies.J Hepatol 2017;67:999-1008[PMID:28687477 DOI:10.1016/j.jhep.2017.06.026]
7 Lin ZZ,Hsu C,Hu FC,Shao YY,Chang DY,Yang CH,Hong RL,Hsu CH,Cheng AL.Factors impacting prognosis prediction in BCLC stage C and Child-Pugh class A hepatocellular carcinoma patients in prospective clinical trials of systemic therapy.Oncologist 2012;17:970-977[PMID:22673633 DOI:10.1634/theoncologist.2011-0411]
8 Shao YY,Lin ZZ,Hsu C,Shen YC,Hsu CH,Cheng AL.Early alpha-fetoprotein response predicts treatment efficacy of antiangiogenic systemic therapy in patients with advanced hepatocellular carcinoma.Cancer 2010;116:4590-4596[PMID:20572033 DOI:10.1002/cncr.25257]
9 Yau T,Yao TJ,Chan P,Wong H,Pang R,Fan ST,Poon RT.The significance of early alpha-fetoprotein level changes in predicting clinical and survival benefits in advanced hepatocellular carcinoma patients receiving sorafenib.Oncologist 2011;16:1270-1279[PMID:21885876 DOI:10.1634/theoncologist.2011-0105]
10 Personeni N,Bozzarelli S,Pressiani T,Rimassa L,Tronconi MC,Sclafani F,Carnaghi C,Pedicini V,Giordano L,Santoro A.Usefulness of alpha-fetoprotein response in patients treated with sorafenib for advanced hepatocellular carcinoma.J Hepatol 2012;57:101-107[PMID:22414760 DOI:10.1016/j.jhep.2012.02.016]
11 Nakazawa T,Hidaka H,Takada J,Okuwaki Y,Tanaka Y,Watanabe M,Shibuya A,Minamino T,Kokubu S,Koizumi W.Early increase inα-fetoprotein for predicting unfavorable clinical outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib.Eur J Gastroenterol Hepatol 2013;25:683-689[PMID:23395995 DOI:10.1097/MEG.0b013e32835d913b]
12 Vincenzi B,Santini D,Russo A,Addeo R,Giuliani F,Montella L,Rizzo S,Venditti O,Frezza AM,Caraglia M,Colucci G,Del Prete S,Tonini G.Early skin toxicity as a predictive factor for tumor control in hepatocellular carcinoma patients treated with sorafenib.Oncologist 2010;15:85-92[PMID:20051477 DOI:10.1634/theoncologist.2009-0143]
13 Reig M,Torres F,Rodriguez-Lope C,Forner A,LLarch N,Rimola J,Darnell A,Ríos J,Ayuso C,Bruix J.Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib.J Hepatol 2014;61:318-324[PMID:24703956 DOI:10.1016/j.jhep.2014.03.030]
14 Wang P,Tan G,Zhu M,Li W,Zhai B,Sun X.Hand-foot skin reaction is a beneficial indicator of sorafenib therapy for patients with hepatocellular carcinoma:a systemic review and metaanalysis.Expert Rev Gastroenterol Hepatol 2018;12:1-8[PMID:28847184 DOI:10.1080/17474124.2017.1373018]
15 Scartozzi M,Galizia E,Chiorrini S,Giampieri R,Berardi R,Pierantoni C,Cascinu S.Arterial hypertension correlates with clinical outcome in colorectal cancer patients treated with first-line bevacizumab.Ann Oncol 2009;20:227-230[PMID:18842611DOI:10.1093/annonc/mdn637]
16 Casadei Gardini A,Scarpi E,Marisi G,Foschi FG,Donati G,Giampalma E,Faloppi L,Scartozzi M,Silvestris N,Bisulli M,Corbelli J,Gardini A,La Barba G,Veneroni L,Tamberi S,Cascinu S,Frassineti GL.Early onset of hypertension and serum electrolyte changes as potential predictive factors of activity in advanced HCCpatients treated with sorafenib:results from a retrospective analysis of the HCC-AVR group.Oncotarget 2016;7:15243-15251[PMID:26893366 DOI:10.18632/oncotarget.7444]
17 Zhong BY,Ni CF,Chen L,Zhu HD,Teng GJ.Early Sorafenibrelated Biomarkers for Combination Treatment with Transarterial Chemoembolization and Sorafenib in Patients with Hepatocellular Carcinoma.Radiology 2017;284:583-592[PMID:28263701DOI:10.1148/radiol.2017161975]
18 Howell J,Pinato DJ,Ramaswami R,Bettinger D,Arizumi T,Ferrari C,Yen C,Gibbin A,Burlone ME,Guaschino G,Sellers L,Black J,Pirisi M,Kudo M,Thimme R,Park JW,Sharma R.On-target sorafenib toxicity predicts improved survival in hepatocellular carcinoma:a multi-centre,prospective study.Aliment Pharmacol Ther 2017;45:1146-1155[PMID:28252185DOI:10.1111/apt.13977]
19 Shin SY,Lee YJ.Correlation of skin toxicity and hypertension with clinical benefit in advanced hepatocellular carcinoma patients treated with sorafenib.Int J Clin Pharmacol Ther 2013;51:837-846[PMID:24075093 DOI:10.5414/CP201907]
20 Otsuka T,Eguchi Y,Kawazoe S,Yanagita K,Ario K,Kitahara K,Kawasoe H,Kato H,Mizuta T;Saga Liver Cancer Study Group.Skin toxicities and survival in advanced hepatocellular carcinoma patients treated with sorafenib.Hepatol Res 2012;42:879-886[PMID:22469363 DOI:10.1111/j.1872-034X.2012.00991.x]
21 Bettinger D,Schultheiss M,Knüppel E,Thimme R,Blum HE,Spangenberg HC.Diarrhea predicts a positive response to sorafenib in patients with advanced hepatocellular carcinoma.Hepatology2012;56:789-790[PMID:22307848 DOI:10.1002/hep.25637]
22 Koschny R,Gotthardt D,Koehler C,Jaeger D,Stremmel W,Ganten TM.Diarrhea is a positive outcome predictor for sorafenib treatment of advanced hepatocellular carcinoma.Oncology2013;84:6-13[PMID:23075905 DOI:10.1159/000342425]
23 Di Costanzo GG,de Stefano G,Tortora R,Farella N,Addario L,Lampasi F,Lanza AG,Cordone G,Imparato M,Caporaso N.Sorafenib off-target effects predict outcomes in patients treated for hepatocellular carcinoma.Future Oncol 2015;11:943-951[PMID:25760975 DOI:10.2217/fon.14.291]
24 Di Costanzo GG,Casadei Gardini A,Marisi G,Foschi FG,Scartozzi M,Granata R,Faloppi L,Cascinu S,Silvestris N,Brunetti O,Palmieri VO,Ercolani G,Tortora R.Validation of a Simple Scoring System to Predict Sorafenib Effectiveness in Patients with Hepatocellular Carcinoma.Target Oncol 2017;12:795-803[PMID:28770532 DOI:10.1007/s11523-017-0522-5]
25 Abdel-Rahman O,Lamarca A.Development of sorafenib-related side effects in patients diagnosed with advanced hepatocellular carcinoma treated with sorafenib:a systematic-review and metaanalysis of the impact on survival.Expert Rev Gastroenterol Hepatol 2017;11:75-83[PMID:27882800 DOI:10.1080/17474124.2017.1264874]
26 Cheng AL,Guan Z,Chen Z,Tsao CJ,Qin S,Kim JS,Yang TS,Tak WY,Pan H,Yu S,Xu J,Fang F,Zou J,Lentini G,Voliotis D,Kang YK.Efficacy and safety of sorafenib in patients with advanced hepatocellular carcinoma according to baseline status:subset analyses of the phase III Sorafenib Asia-Pacific trial.Eur J Cancer 2012;48:1452-1465[PMID:22240282 DOI:10.1016/j.ejca.2011.12.006]
27 Hollebecque A,Cattan S,Romano O,Sergent G,Mourad A,Louvet A,Dharancy S,Boleslawski E,Truant S,Pruvot FR,Hebbar M,Ernst O,Mathurin P.Safety and efficacy of sorafenib in hepatocellular carcinoma:the impact of the Child-Pugh score.Aliment Pharmacol Ther 2011;34:1193-1201[PMID:21958438DOI:10.1111/j.1365-2036.2011.04860.x]
28 Pressiani T,Boni C,Rimassa L,Labianca R,Fagiuoli S,Salvagni S,Ferrari D,Cortesi E,Porta C,Mucciarini C,Latini L,Carnaghi C,Banzi M,Fanello S,De Giorgio M,Lutman FR,Torzilli G,Tommasini MA,Ceriani R,Covini G,Tronconi MC,Giordano L,Locopo N,Naimo S,Santoro A.Sorafenib in patients with Child-Pugh class A and B advanced hepatocellular carcinoma:a prospective feasibility analysis.Ann Oncol 2013;24:406-411[PMID:23041587 DOI:10.1093/annonc/mds343]
29 Marrero JA,Kudo M,Venook AP,Ye SL,Bronowicki JP,Chen XP,Dagher L,Furuse J,Geschwind JH,de Guevara LL,Papandreou C,Takayama T,Sanyal AJ,Yoon SK,Nakajima K,Lehr R,Heldner S,Lencioni R.Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups:The GIDEONstudy.J Hepatol 2016;65:1140-1147[PMID:27469901 DOI:10.1016/j.jhep.2016.07.020]
30 Lee S,Kang JH,Kim DY,Ahn SH,Park JY,Kim BK,Kim SU,Han KH.Prognostic factors of sorafenib therapy in hepatocellular carcinoma patients with failure of transarterial chemoembolization.Hepatol Int 2017;11:292-299[PMID:28324324 DOI:10.1007/s12072-017-9792-3]
31 Peng S,Zhao Y,Xu F,Jia C,Xu Y,Dai C.An updated metaanalysis of randomized controlled trials assessing the effect of sorafenib in advanced hepatocellular carcinoma.PLo S One2014;9:e112530[PMID:25460347 DOI:10.1371/journal.pone.0112530]
32 Iavarone M,Cabibbo G,Piscaglia F,Zavaglia C,Grieco A,Villa E,CammàC,Colombo M;SOFIA(SOraFenib Italian Assessment)study group.Field-practice study of sorafenib therapy for hepatocellular carcinoma:a prospective multicenter study in Italy.Hepatology 2011;54:2055-2063[PMID:21898496 DOI:10.1002/hep.24644]
33 Casadei Gardini A,Frassineti GL,Foschi FG,Ercolani G,Ulivi P.Sorafenib and Regorafenib in HBV-or HCV-positive hepatocellular carcinoma patients:Analysis of RESORCE and SHARP trials.Dig Liver Dis 2017;49:943-944[PMID:28546063DOI:10.1016/j.dld.2017.04.022]
34 Donadon V,Balbi M,Mas MD,Casarin P,Zanette G.Metformin and reduced risk of hepatocellular carcinoma in diabetic patients with chronic liver disease.Liver Int 2010;30:750-758[PMID:20331505 DOI:10.1111/j.1478-3231.2010.02223.x]
35 Casadei Gardini A,Marisi G,Scarpi E,Scartozzi M,Faloppi L,Silvestris N,Masi G,Vivaldi C,Brunetti O,Tamberi S,Foschi FG,Tamburini E,Tenti E,Ricca Rosellini S,Ulivi P,Cascinu S,Nanni O,Frassineti GL.Effects of metformin on clinical outcome in diabetic patients with advanced HCC receiving sorafenib.Expert Opin Pharmacother 2015;16:2719-2725[PMID:26513009 DOI:10.1517/14656566.2015.1102887]
36 Casadei Gardini A,Faloppi L,De Matteis S,Foschi FG,Silvestris N,Tovoli F,Palmieri V,Marisi G,Brunetti O,VespasianiGentilucci U,Perrone G,Valgiusti M,Granato AM,Ercolani G,Negrini G,Tamburini E,Aprile G,Passardi A,Santini D,Cascinu S,Frassineti GL,Scartozzi M.Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib:Validation study and biological rationale.Eur J Cancer 2017;86:106-114[PMID:28985579 DOI:10.1016/j.ejca.2017.09.003]
37 De Matteis S,Granato AM,Napolitano R,Molinari C,Valgiusti M,Santini D,Foschi FG,Ercolani G,Vespasiani Gentilucci U,Faloppi L,Scartozzi M,Frassineti GL,Casadei Gardini A.Interplay Between SIRT-3,Metabolism and Its Tumor Suppressor Role in Hepatocellular Carcinoma.Dig Dis Sci 2017;62:1872-1880[PMID:28527050 DOI:10.1007/s10620-017-4615-x]
38 Di Costanzo GG,Tortora R,Morisco F,Addario L,Guarino M,Cordone G,Falco L,Caporaso N.Impact of Diabetes on Outcomes of Sorafenib Therapy for Hepatocellular Carcinoma.Target Oncol 2017;12:61-67[PMID:27503006 DOI:10.1007/s11523-016-0454-5]
39 Ferrucci PF,Gandini S,Battaglia A,Alfieri S,Di Giacomo AM,Giannarelli D,Cappellini GC,De Galitiis F,Marchetti P,Amato G,Lazzeri A,Pala L,Cocorocchio E,Martinoli C.Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients.Br J Cancer 2015;112:1904-1910[PMID:26010413 DOI:10.1038/bjc.2015.180]
40 Hu B,Yang XR,Xu Y,Sun YF,Sun C,Guo W,Zhang X,Wang WM,Qiu SJ,Zhou J,Fan J.Systemic immune-inflammation index predicts prognosis of patients after curative resection for hepatocellular carcinoma.Clin Cancer Res 2014;20:6212-6222[PMID:25271081 DOI:10.1158/1078-0432.CCR-14-0442]
41 Casadei Gardini A,Scarpi E,Faloppi L,Scartozzi M,Silvestris N,Santini D,de Stefano G,Marisi G,Negri FV,Foschi FG,Valgiusti M,Ercolani G,Frassineti GL.Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib.Oncotarget 2016;7:67142-67149[PMID:27613839 DOI:10.18632/oncotarget.11565]
42 Howell J,Pinato DJ,Ramaswami R,Arizumi T,Ferrari C,Gibbin A,Burlone ME,Guaschino G,Toniutto P,Black J,Sellers L,Kudo M,Pirisi M,Sharma R.Integration of the cancer-related inflammatory response as a stratifying biomarker of survival in hepatocellular carcinoma treated with sorafenib.Oncotarget 2017;8:36161-36170[PMID:28212535 DOI:10.18632/oncotarget.15322]
43 da Fonseca LG,Barroso-Sousa R,Bento Ada S,Blanco BP,Valente GL,Pfiffer TE,Hoff PM,Sabbaga J.Pre-treatment neutrophil-to-lymphocyte ratio affects survival in patients with advanced hepatocellular carcinoma treated with sorafenib.Med Oncol 2014;31:264[PMID:25273866 DOI:10.1007/s12032-014-0264-5]
44 LuéA,Serrano MT,Bustamante FJ,I?arrairaegui M,Arenas JI,Testillano M,Lorente S,Gil C,de la Torre M,Gomez A,Sangro B.Neutrophil-to-lymphocyte ratio predicts survival in European patients with hepatocellular carcinoma administered sorafenib.Oncotarget 2017;8:103077-103086[PMID:29262546 DOI:10.18632/oncotarget.21528]
45 Therasse P,Arbuck SG,Eisenhauer EA,Wanders J,Kaplan RS,Rubinstein L,Verweij J,Van Glabbeke M,van Oosterom AT,Christian MC,Gwyther SG.New guidelines to evaluate the response to treatment in solid tumors.European Organization for Research and Treatment of Cancer,National Cancer Institute of the United States,National Cancer Institute of Canada.J Natl Cancer Inst 2000;92:205-216[PMID:10655437]
46 Eisenhauer EA,Therasse P,Bogaerts J,Schwartz LH,Sargent D,Ford R,Dancey J,Arbuck S,Gwyther S,Mooney M,Rubinstein L,Shankar L,Dodd L,Kaplan R,Lacombe D,Verweij J.New response evaluation criteria in solid tumours:revised RECISTguideline(version 1.1).Eur J Cancer 2009;45:228-247[PMID:19097774 DOI:10.1016/j.ejca.2008.10.026]
47 Ronot M,Bouattour M,Wassermann J,Bruno O,Dreyer C,Larroque B,Castera L,Vilgrain V,Belghiti J,Raymond E,Faivre S.Alternative Response Criteria(Choi,European association for the study of the liver,and modified Response Evaluation Criteria in Solid Tumors[RECIST])Versus RECIST 1.1 in patients with advanced hepatocellular carcinoma treated with sorafenib.Oncologist 2014;19:394-402[PMID:24652387 DOI:10.1634/theoncologist.2013-0114]
48 Sugimoto K,Moriyasu F,Saito K,Rognin N,Kamiyama N,Furuichi Y,Imai Y.Hepatocellular carcinoma treated with sorafenib:early detection of treatment response and major adverse events by contrast-enhanced US.Liver Int 2013;33:605-615[PMID:23305331 DOI:10.1111/liv.12098]
49 Zocco MA,Garcovich M,Lupascu A,Di Stasio E,Roccarina D,Annicchiarico BE,Riccardi L,Ainora ME,Ponziani F,Caracciolo G,Rapaccini GL,Landolfi R,Siciliano M,Pompili M,Gasbarrini A.Early prediction of response to sorafenib in patients with advanced hepatocellular carcinoma:the role of dynamic contrast enhanced ultrasound.J Hepatol 2013;59:1014-1021[PMID:23811306 DOI:10.1016/j.jhep.2013.06.011]
50 Zhou C,Liu J,Li Y,Liu L,Zhang X,Ma CY,Hua SC,Yang M,Yuan Q.microRNA-1274a,a modulator of sorafenib induced a disintegrin and metalloproteinase 9(ADAM9)down-regulation in hepatocellular carcinoma.FEBS Lett 2011;585:1828-1834[PMID:21530512 DOI:10.1016/j.febslet.2011.04.040]
51 Hsu CY,Shen YC,Yu CW,Hsu C,Hu FC,Hsu CH,Chen BB,Wei SY,Cheng AL,Shih TT.Dynamic contrast-enhanced magnetic resonance imaging biomarkers predict survival and response in hepatocellular carcinoma patients treated with sorafenib and metronomic tegafur/uracil.J Hepatol 2011;55:858-865[PMID:21338641 DOI:10.1016/j.jhep.2011.01.032]
52 Lee JH,Park JY,Kim DY,Ahn SH,Han KH,Seo HJ,Lee JD,Choi HJ.Prognostic value of 18F-FDG PET for hepatocellular carcinoma patients treated with sorafenib.Liver Int 2011;31:1144-1149[PMID:21745288 DOI:10.1111/j.1478-3231.2011.02541.x]
53 MuléS,Thiefin G,Costentin C,Durot C,Rahmouni A,Luciani A,Hoeffel C.Advanced Hepatocellular Carcinoma:Pretreatment Contrast-enhanced CT Texture Parameters as Predictive Biomarkers of Survival in Patients Treated with Sorafenib.Radiology 2018;288:445-455[PMID:29584597 DOI:10.1148/radiol.2018171320]
54 Su WW,Lee KT,Yeh YT,Soon MS,Wang CL,Yu ML,Wang SN.Association of circulating insulin-like growth factor 1 with hepatocellular carcinoma:one cross-sectional correlation study.JClin Lab Anal 2010;24:195-200[PMID:20486202 DOI:10.1002/jcla.20320]
55 Shao YY,Huang CC,Lin SD,Hsu CH,Cheng AL.Serum insulinlike growth factor-1 levels predict outcomes of patients with advanced hepatocellular carcinoma receiving antiangiogenic therapy.Clin Cancer Res 2012;18:3992-3997[PMID:22623732DOI:10.1158/1078-0432.CCR-11-2853]
56 Kim HY,Lee DH,Lee JH,Cho YY,Cho EJ,Yu SJ,Kim YJ,Yoon JH.Novel biomarker-based model for the prediction of sorafenib response and overall survival in advanced hepatocellular carcinoma:a prospective cohort study.BMC Cancer 2018;18:307[PMID:29558905 DOI:10.1186/s12885-018-4211-2]
57 Miyahara K,Nouso K,Tomoda T,Kobayashi S,Hagihara H,Kuwaki K,Toshimori J,Onishi H,Ikeda F,Miyake Y,Nakamura S,Shiraha H,Takaki A,Yamamoto K.Predicting the treatment effect of sorafenib using serum angiogenesis markers in patients with hepatocellular carcinoma.J Gastroenterol Hepatol 2011;26:1604-1611[PMID:22011296 DOI:10.1111/j.1440-1746.2011.06887.x]
58 Tsuchiya K,Asahina Y,Matsuda S,Muraoka M,Nakata T,Suzuki Y,Tamaki N,Yasui Y,Suzuki S,Hosokawa T,Nishimura T,Ueda K,Kuzuya T,Nakanishi H,Itakura J,Takahashi Y,Kurosaki M,Enomoto N,Izumi N.Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma.Cancer 2014;120:229-237[PMID:24122122 DOI:10.1002/cncr.28384]
59 Hu B,Cheng SY.Angiopoietin-2:development of inhibitors for cancer therapy.Curr Oncol Rep 2009;11:111-116[PMID:19216842]
60 Hayashi T,Yamashita T,Terashima T,Suda T,Okada H,Asahina Y,Hayashi T,Hara Y,Nio K,Sunagozaka H,Takatori H,Arai K,Sakai Y,Yamashita T,Mizukoshi E,Honda M,Kaneko S.Serum cytokine profiles predict survival benefits in patients with advanced hepatocellular carcinoma treated with sorafenib:a retrospective cohort study.BMC Cancer 2017;17:870[PMID:29258450 DOI:10.1186/s12885-017-3889-x]
61 Villanueva A,Minguez B,Forner A,Reig M,Llovet JM.Hepatocellular carcinoma:novel molecular approaches for diagnosis,prognosis,and therapy.Annu Rev Med 2010;61:317-328[PMID:20059340 DOI:10.1146/annurev.med.080608.100623]
62 Sakai K,Takeda H,Nishijima N,Orito E,Joko K,Uchida Y,Izumi N,Nishio K,Osaki Y.Targeted DNA and RNA sequencing of fine-needle biopsy FFPE specimens in patients with unresectable hepatocellular carcinoma treated with sorafenib.Oncotarget2015;6:21636-21644[PMID:26046304 DOI:10.18632/oncotarget.4270]
63 Kan Z,Zheng H,Liu X,Li S,Barber TD,Gong Z,Gao H,Hao K,Willard MD,Xu J,Hauptschein R,Rejto PA,Fernandez J,Wang G,Zhang Q,Wang B,Chen R,Wang J,Lee NP,Zhou W,Lin Z,Peng Z,Yi K,Chen S,Li L,Fan X,Yang J,Ye R,Ju J,Wang K,Estrella H,Deng S,Wei P,Qiu M,Wulur IH,Liu J,Ehsani ME,Zhang C,Loboda A,Sung WK,Aggarwal A,Poon RT,Fan ST,Wang J,Hardwick J,Reinhard C,Dai H,Li Y,Luk JM,Mao M.Wholegenome sequencing identifies recurrent mutations in hepatocellular carcinoma.Genome Res 2013;23:1422-1433[PMID:23788652DOI:10.1101/gr.154492.113]
64 Cleary SP,Jeck WR,Zhao X,Chen K,Selitsky SR,Savich GL,Tan TX,Wu MC,Getz G,Lawrence MS,Parker JS,Li J,Powers S,Kim H,Fischer S,Guindi M,Ghanekar A,Chiang DY.Identification of driver genes in hepatocellular carcinoma by exome sequencing.Hepatology 2013;58:1693-1702[PMID:23728943DOI:10.1002/hep.26540]
65 Scartozzi M,Faloppi L,Svegliati Baroni G,Loretelli C,Piscaglia F,Iavarone M,Toniutto P,Fava G,De Minicis S,Mandolesi A,Bianconi M,Giampieri R,Granito A,Facchetti F,Bitetto D,Marinelli S,Venerandi L,Vavassori S,Gemini S,D’Errico A,Colombo M,Bolondi L,Bearzi I,Benedetti A,Cascinu S.VEGFand VEGFR genotyping in the prediction of clinical outcome for HCC patients receiving sorafenib:the ALICE-1 study.Int J Cancer2014;135:1247-1256[PMID:24510746 DOI:10.1002/ijc.28772]
66 Casadei Gardini A,Marisi G,Faloppi L,Scarpi E,Foschi FG,Iavarone M,Lauletta G,Corbelli J,Valgiusti M,Facchetti F,Della Corte C,Neri LM,Tamberi S,Cascinu S,Scartozzi M,Amadori D,Nanni O,Tenti E,Ulivi P,Frassineti GL.eNOS polymorphisms and clinical outcome in advanced HCC patients receiving sorafenib:final results of the ePHAS study.Oncotarget 2016;7:27988-27999[PMID:27058899 DOI:10.18632/oncotarget.8569]
67 Marisi G,Scartozzi M,Faloppi L,Foschi GF,Lauletta G,Valgiusti M,Aprile G,Fornaro L,Iavarone M,Ercolani G,Frassineti GL,Amadori D,Casadei Gardini A.Ang-2 polymorphisms in relation to outcome in advanced HCC patients receiving sorafenib.J Clin Oncol 2017;35 Suppl 15:e15666[DOI:10.1200/JCO.2017.35.15_suppl.e15666]
68 Faloppi L,Casadei Gardini A,Masi G,Silvestris N,Loretelli C,Ulivi P,Vivaldi C,Bianconi M,Giampieri R,Bittoni A,Andrikou K,Del Prete M,Scartozzi M,Cascinu S.Angiogenesis polymorphisms profile in the prediction of clinical outcome of advanced HCCpatients receiving sorafenib:Combined analysis of VEGF and HIF-1α.Final results of the ALICE-2 study.J Clin Oncol 2016;34Suppl 4:280[DOI:10.1200/jco.2016.34.4_suppl.280]
69 Casadei Gardini A,Faloppi L,Aprile G,Brunetti O,Caparello C,Corbelli J,Chessa L,Bruno D,Ercolani G,Leonetti A,de Stefano G,Farella N,Foschi FG,Lanzi A,Dadduzio V,Marisi G,Masi G,Negri FV,Pagan F,Santini D,Scarpi E,Silletta M,Silvestris N,Tamburini E,Tassinari D,Vivaldi C,Gentilucci UV,Zagonel V,Calvetti L,Cascinu S,Frassineti GL,Scartozzi M.Multicenter Prospective Study of Angiogenesis Polymorphism Validation in HCC Patients Treated with Sorafenib.An INNOVATE Study Protocol.Tumori 2017;:tj5000704 Epub ahead of print[PMID:29739298 DOI:10.5301/tj.5000704]
70 Horwitz E,Stein I,Andreozzi M,Nemeth J,Shoham A,Pappo O,Schweitzer N,Tornillo L,Kanarek N,Quagliata L,Zreik F,Porat RM,Finkelstein R,Reuter H,Koschny R,Ganten T,Mogler C,Shibolet O,Hess J,Breuhahn K,Grunewald M,Schirmacher P,Vogel A,Terracciano L,Angel P,Ben-Neriah Y,Pikarsky E.Human and mouse VEGFA-amplified hepatocellular carcinomas are highly sensitive to sorafenib treatment.Cancer Discov 2014;4:730-743[PMID:24687604 DOI:10.1158/2159-8290.CD-13-0782]
71 Arao T,Ueshima K,Matsumoto K,Nagai T,Kimura H,Hagiwara S,Sakurai T,Haji S,Kanazawa A,Hidaka H,Iso Y,Kubota K,Shimada M,Utsunomiya T,Hirooka M,Hiasa Y,Toyoki Y,Hakamada K,Yasui K,Kumada T,Toyoda H,Sato S,Hisai H,Kuzuya T,Tsuchiya K,Izumi N,Arii S,Nishio K,Kudo M.FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma.Hepatology 2013;57:1407-1415[PMID:22890726 DOI:10.1002/hep.25956]
72 He C,Dong X,Zhai B,Jiang X,Dong D,Li B,Jiang H,Xu S,Sun X.MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.Oncotarget 2015;6:28867-28881[PMID:26311740DOI:10.18632/oncotarget.4814]
73 Xu Y,Huang J,Ma L,Shan J,Shen J,Yang Z,Liu L,Luo Y,Yao C,Qian C.MicroRNA-122 confers sorafenib resistance to hepatocellular carcinoma cells by targeting IGF-1R to regulate RAS/RAF/ERK signaling pathways.Cancer Lett 2016;371:171-181[PMID:26655273 DOI:10.1016/j.canlet.2015.11.034]
74 Vaira V,Roncalli M,Carnaghi C,Faversani A,Maggioni M,Augello C,Rimassa L,Pressiani T,Spagnuolo G,Di Tommaso L,Fagiuoli S,Rota Caremoli E,Barberis M,Labianca R,Santoro A,Bosari S.MicroRNA-425-3p predicts response to sorafenib therapy in patients with hepatocellular carcinoma.Liver Int 2015;35:1077-1086[PMID:25040368 DOI:10.1111/liv.12636]
75 Gy?ngy?si B,Véghé,Járay B,Székely E,Fassan M,Bodoky G,Schaff Z,Kiss A.Pretreatment MicroRNA Level and Outcome in Sorafenib-treated Hepatocellular Carcinoma.J Histochem Cytochem 2014;62:547-555[PMID:24804874 DOI:10.1369/0022155414537277]
76 Fornari F,Pollutri D,Patrizi C,La Bella T,Marinelli S,Casadei Gardini A,Marisi G,Baron Toaldo M,Baglioni M,Salvatore V,Callegari E,Baldassarre M,Galassi M,Giovannini C,Cescon M,Ravaioli M,Negrini M,Bolondi L,Gramantieri L.In Hepatocellular Carcinoma miR-221 Modulates Sorafenib Resistance through Inhibition of Caspase-3-Mediated Apoptosis.Clin Cancer Res2017;23:3953-3965[PMID:28096271 DOI:10.1158/1078-0432.CCR-16-1464]
77 Nishida N,Arizumi T,Hagiwara S,Ida H,Sakurai T,Kudo M.MicroRNAs for the Prediction of Early Response to Sorafenib Treatment in Human Hepatocellular Carcinoma.Liver Cancer2017;6:113-125[PMID:28275578 DOI:10.1159/000449475]
78 Stiuso P,Potenza N,Lombardi A,Ferrandino I,Monaco A,Zappavigna S,Vanacore D,Mosca N,Castiello F,Porto S,Addeo R,Prete SD,De Vita F,Russo A,Caraglia M.MicroRNA-423-5p Promotes Autophagy in Cancer Cells and Is Increased in Serum From Hepatocarcinoma Patients Treated With Sorafenib.Mol Ther Nucleic Acids 2015;4:e233[PMID:25782064 DOI:10.1038/mtna.2015.8]
79 Yoon EL,Yeon JE,Ko E,Lee HJ,Je JH,Yoo YJ,Kang SH,Suh SJ,Kim JH,Seo YS,Yim HJ,Byun KS.An Explorative Analysis for the Role of Serum miR-10b-3p Levels in Predicting Response to Sorafenib in Patients with Advanced Hepatocellular Carcinoma.J Korean Med Sci 2017;32:212-220[PMID:28049231 DOI:10.3346/jkms.2017.32.2.212]
80 Carvajal-Hausdorf DE,Schalper KA,Neumeister VM,Rimm DL.Quantitative measurement of cancer tissue biomarkers in the lab and in the clinic.Lab Invest 2015;95:385-396[PMID:25502176 DOI:10.1038/labinvest.2014.157]
81 Abou-Alfa GK,Schwartz L,Ricci S,Amadori D,Santoro A,Figer A,De Greve J,Douillard JY,Lathia C,Schwartz B,Taylor I,Moscovici M,Saltz LB.Phase II study of sorafenib in patients with advanced hepatocellular carcinoma.J Clin Oncol 2006;24:4293-4300[PMID:16908937 DOI:10.1200/JCO.2005.01.3441]
82 Personeni N,Rimassa L,Pressiani T,Destro A,Ligorio C,Tronconi MC,Bozzarelli S,Carnaghi C,Di Tommaso L,Giordano L,Roncalli M,Santoro A.Molecular determinants of outcome in sorafenib-treated patients with hepatocellular carcinoma.J Cancer Res Clin Oncol 2013;139:1179-1187[PMID:23568548 DOI:10.1007/s00432-013-1429-x]
83 Chen D,Zhao P,Li SQ,Xiao WK,Yin XY,Peng BG,Liang LJ.Prognostic impact of pERK in advanced hepatocellular carcinoma patients treated with sorafenib.Eur J Surg Oncol 2013;39:974-980[PMID:23845703 DOI:10.1016/j.ejso.2013.06.018]
84 Chu JS,Ge FJ,Zhang B,Wang Y,Silvestris N,Liu LJ,Zhao CH,Lin L,Brunetti AE,Fu YL,Wang J,Paradiso A,Xu JM.Expression and prognostic value of VEGFR-2,PDGFR-β,and c-Met in advanced hepatocellular carcinoma.J Exp Clin Cancer Res 2013;32:16[PMID:23552472 DOI:10.1186/1756-9966-32-16]
85 Hagiwara S,Kudo M,Nagai T,Inoue T,Ueshima K,Nishida N,Watanabe T,Sakurai T.Activation of JNK and high expression level of CD133 predict a poor response to sorafenib in hepatocellular carcinoma.Br J Cancer 2012;106:1997-2003[PMID:22596232 DOI:10.1038/bjc.2012.145]
86 Kudo M,Finn RS,Qin S,Han KH,Ikeda K,Piscaglia F,Baron A,Park JW,Han G,Jassem J,Blanc JF,Vogel A,Komov D,Evans TRJ,Lopez C,Dutcus C,Guo M,Saito K,Kraljevic S,Tamai T,Ren M,Cheng AL.Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma:a randomised phase 3 non-inferiority trial.Lancet2018;391:1163-1173[PMID:29433850 DOI:10.1016/S0140-6736(18)30207-1]